OP 07
Real experience of brentuximab vedotin for cutaneous T cell lymphomas
Ege University, Department of Hematology, Izmir, Turkey
Lido
2593
Vezesque se leu este artigo
1125
Total PDF
1468
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 19 | 9 | 28 |
| 2025 5 | 54 | 12 | 66 |
| 2025 4 | 44 | 14 | 58 |
| 2025 3 | 45 | 10 | 55 |
| 2025 2 | 28 | 16 | 44 |
| 2025 1 | 34 | 20 | 54 |
| 2024 12 | 31 | 14 | 45 |
| 2024 11 | 31 | 16 | 47 |
| 2024 10 | 20 | 23 | 43 |
| 2024 9 | 29 | 28 | 57 |
| 2024 8 | 28 | 19 | 47 |
| 2024 7 | 30 | 20 | 50 |
| 2024 6 | 34 | 29 | 63 |
| 2024 5 | 27 | 23 | 50 |
| 2024 4 | 27 | 16 | 43 |
| 2024 3 | 22 | 18 | 40 |
| 2024 2 | 29 | 24 | 53 |
| 2024 1 | 28 | 24 | 52 |
| 2023 12 | 24 | 28 | 52 |
| 2023 11 | 47 | 44 | 91 |
| 2023 10 | 34 | 26 | 60 |
| 2023 9 | 32 | 34 | 66 |
| 2023 8 | 26 | 10 | 36 |
| 2023 7 | 30 | 10 | 40 |
| 2023 6 | 32 | 24 | 56 |
| 2023 5 | 32 | 14 | 46 |
| 2023 4 | 21 | 9 | 30 |
| 2023 3 | 31 | 19 | 50 |
| 2023 2 | 27 | 12 | 39 |
| 2023 1 | 31 | 12 | 43 |
| 2022 12 | 22 | 29 | 51 |
| 2022 11 | 33 | 23 | 56 |
| 2022 10 | 32 | 20 | 52 |
| 2022 9 | 27 | 23 | 50 |
| 2022 8 | 23 | 22 | 45 |
| 2022 7 | 23 | 25 | 48 |
| 2022 6 | 18 | 17 | 35 |
| 2022 5 | 16 | 16 | 32 |
| 2022 4 | 32 | 19 | 51 |
| 2022 3 | 23 | 18 | 41 |
| 2022 2 | 20 | 19 | 39 |
| 2021 1 | 15 | 13 | 28 |
| 2021 12 | 18 | 21 | 39 |
| 2021 11 | 23 | 23 | 46 |
| 2021 10 | 21 | 29 | 50 |
| 2021 9 | 21 | 21 | 42 |
| 2021 8 | 19 | 24 | 43 |
| 2021 7 | 12 | 26 | 38 |
| 2021 6 | 15 | 24 | 39 |
| 2021 5 | 28 | 30 | 58 |
| 2021 4 | 44 | 27 | 71 |
| 2021 3 | 23 | 26 | 49 |
| 2021 2 | 11 | 18 | 29 |
| 2020 1 | 11 | 17 | 28 |
| 2020 12 | 5 | 7 | 12 |
| 2020 11 | 6 | 11 | 17 |
Mostrar tudo
